Are glucagon-like peptide 1 analogues effective and safe in severe COVID-19 patients with type 2 diabetes?—a case report

: Many cases of novel coronavirus 2019 (COVID-19) have confirmed in many countries around the world. Due to disorders immune system, diabetic patients are more likely suffer from severe COVID-19. Glucagon-like peptide 1 analogues (GLP-1 analogues) commonly can be used reduce blood sugar. There is no clear evidence that it safely and effectively with diabetes merged In this case, we described A 65-year-old male hypertension was diagnosed COVID-19, he took liraglutide at doses ranging 0.8 1.8 mg. Before admission, not glucose. Hydroxychloroquine sulfate abidol were antivirus supportive treatment simultaneously during hospitalization. During treatment, patient’s own state paid attention to, glucose, liver function, kidney white cells, lymphocytes other indicators checked chest CT reviewed regularly, which could reflect changes disease. After glucose under control, his renal normal also improved. The case showed may effective safe COVID-19 combined type 2 diabetes, but clinical trials needed.